Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Anticuerpos Monoclonales Humanizados
/
Receptor de Muerte Celular Programada 1
/
Neoplasias Pulmonares
/
Melanoma
/
Anticuerpos Monoclonales
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Cell
Año:
2015
Tipo del documento:
Article